[EN] COMPOSITIONS COMPRISING TRYPSIN-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS DE TYPE AMPHÉTAMINE CLIVABLES PAR TRYPSINE ET LEURS INHIBITEURS
申请人:PHARMACOFORE INC
公开号:WO2011133347A1
公开(公告)日:2011-10-27
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.
[EN] COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF<br/>[FR] COMPOSITIONS COMPRENANT DES PROMÉDICAMENTS DE TYPE AMPHÉTAMINE CLIVABLES PAR ENZYME ET LEURS INHIBITEURS
申请人:PHARMACOFORE INC
公开号:WO2011133348A1
公开(公告)日:2011-10-27
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.
Immunoassay for Phenethylamines of the 2C and DO Sub-Families
申请人:Randox Laboratories Limited
公开号:US20150038366A1
公开(公告)日:2015-02-05
Immunoassay methods and their requisite components for the detection and determination of phenethylamines of the 2C and DO sub-families are described.
描述了用于检测和测定2C和DO亚家族苯乙胺的免疫分析方法及其必要组成部分。
Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
申请人:Jenkins Thomas E.
公开号:US20130059914A1
公开(公告)日:2013-03-07
Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise an amphetamine prodrug that provides enzymatically-controlled release of amphetamine or an amphetamine analog. The composition can further comprise an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of amphetamine or the amphetamine analog from the amphetamine prodrug so as to attenuate enzymatic cleavage of the amphetamine prodrug.